Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Cantor Fitzgerald
Boehringer Ingelheim
Covington
Chubb
Johnson and Johnson
QuintilesIMS
Medtronic

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,388,941

« Back to Dashboard

Which drugs does patent 8,388,941 protect, and when does it expire?

Patent 8,388,941 protects TRAVATAN Z and is included in one NDA.

This patent has fifteen patent family members in twelve countries.
Summary for Patent: 8,388,941
Title:Self preserved aqueous pharmaceutical compositions
Abstract: The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being `self-preserved`. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
Inventor(s): Chowhan; Masood A. (Arlington, TX), Keith; David J. (Washington, MO)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:12/441,995
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,388,941
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,388,941

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,388,941

PCT Information
PCT FiledSeptember 20, 2007PCT Application Number:PCT/US2007/079094
PCT Publication Date:April 10, 2008PCT Publication Number: WO2008/042619

International Family Members for US Patent 8,388,941

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007304996 ➤ Try a Free Trial
Brazil PI0717093 ➤ Try a Free Trial
Canada 2663817 ➤ Try a Free Trial
China 101522171 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Colorcon
Boehringer Ingelheim
Express Scripts
UBS
Moodys
Daiichi Sankyo
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.